haemophagocyt
syndrom
haemophagocyt
lymphohistiocytosi
rare
diseas
often
fatal
despit
treatment
haemophagocyt
syndrom
caus
dysregul
natur
killer
tcell
function
result
activ
prolifer
lymphocyt
histiocyt
uncontrol
haemophagocytosi
cytokin
overproduct
syndrom
characteris
fever
hepatosplenomegali
cytopenia
liver
dysfunct
hyperferritinaemia
haemophagocyt
syndrom
either
primari
genet
aetiolog
secondari
associ
malign
autoimmun
diseas
infect
infect
associ
haemophagocyt
syndrom
frequent
caus
virus
particularli
epsteinbarr
viru
ebv
present
case
ebvassoci
haemophagocyt
syndrom
young
adult
known
immunosuppress
briefl
review
haemophagocyt
syndrom
discuss
associ
infect
particularli
ebv
herp
virus
hiv
infl
uenza
parvoviru
hepat
virus
well
bacteri
fungal
parasit
organ
haemophagocyt
syndrom
rare
potenti
fatal
diseas
result
dysregul
activ
prolifer
lymphocyt
describ
case
haemophagocyt
syndrom
associ
epsteinbarr
viru
ebv
discuss
common
infect
associ
syndrom
yearold
white
woman
present
histori
fever
fatigu
kg
weight
loss
patient
complain
occasion
headach
without
neck
stiff
ness
photophobia
short
breath
exert
occasion
nausea
past
medic
histori
signifi
cant
holtoram
syndrom
autosomaldomin
condit
characteris
congenit
cardiac
forelimb
anomali
month
age
patient
surgic
repair
anomal
pulmonari
venou
return
ventricular
septal
defect
patent
ductu
arteriosu
patient
usual
state
health
year
present
primari
ebv
infect
diagnos
posit
serolog
posit
ebv
pcr
assay
episod
result
sever
pancytopenia
bone
marrow
biopsi
done
time
nondiagnost
blood
count
normalis
repeat
ebv
pcr
month
admiss
neg
histori
recurr
infect
patient
colleg
student
abstain
sexual
activ
tobacco
alcohol
illicit
drug
use
recent
travel
tick
bite
mother
brother
holtoram
syndrom
physic
examin
patient
acut
distress
temperatur
heart
rate
beat
per
min
blood
pressur
mm
hg
neck
suppl
cardiovascular
examin
reveal
grade
systol
murmur
left
upper
sternal
border
unchang
previou
examin
truncat
upper
extrem
miss
digit
hand
congenit
syndrom
fi
gure
rash
note
organomegali
palpabl
lymphadenopathi
rest
physic
examin
unremark
laboratori
evalu
reveal
total
leucocyt
count
cell
per
band
form
neutrophil
lymphocyt
monocyt
normocyt
anaemia
hematocrit
thrombocytopenia
platelet
count
per
intern
normalis
ratio
inr
activ
partial
thromboplastin
time
aptt
ratio
normal
lactat
dehydrogenas
iul
normal
liver
transaminas
bilirubin
haptoglobin
level
multipl
cultur
blood
urin
sputum
neg
bacteria
mycobacteria
fungi
serolog
studi
hepat
b
c
cytomegaloviru
parvoviru
ehrlichia
neg
igg
antibodi
toxoplasma
posit
igm
antibodi
neg
consist
previou
infect
serum
cryptococc
antigen
test
urin
histoplasma
antigen
test
neg
test
ebv
capsid
igg
antibodi
ebv
nuclear
antigen
posit
ebv
capsid
antigen
igm
antibodi
neg
howev
ebv
serum
pcr
result
copi
per
ml
use
realart
ebv
pcr
kit
artu
san
francisco
ca
usa
cutoff
copi
per
ml
bone
marrow
biopsi
admiss
show
dysplasia
cell
line
fi
brosi
cytogenet
normal
patient
start
ceftazidim
g
intraven
three
time
day
neutropen
fever
ebv
grand
round
infect
receiv
valaciclovir
g
three
time
day
follow
aciclovir
intraven
one
dose
cidofovir
mgkg
intraven
nonsteroid
antiinfl
ammatori
drug
steroid
given
symptomat
relief
fever
receiv
sever
blood
transfus
variou
dose
granulocytemacrophag
colonystimul
factor
gmcsf
inject
pancytopenia
fever
persist
reach
high
subsequ
develop
progress
hepato
splenomegali
generalis
tender
lymphadenopathi
ct
scan
hospit
day
reveal
three
new
lung
nodul
diff
use
neck
adenopathi
hepatosplenomegali
bronchoscopi
lavag
show
activ
haemorrhag
stain
pneumocysti
jirovecii
fungal
infect
acid
fast
bacilli
cytomegaloviru
herp
simplex
viru
hsv
neg
lung
biopsi
nodul
reveal
acut
organis
pneumonia
nuclear
debri
suggest
possibl
viral
origin
howev
immunoperoxidas
stain
cytomegaloviru
hsv
adenoviru
ebv
well
fungal
stain
neg
transjugular
liver
biopsi
show
centrizon
hepatocyt
dropout
damag
sinusoid
histiocyt
infi
ltrate
stain
neg
hospit
day
patient
increas
respiratori
distress
follow
alter
mental
statu
multiorgan
failur
nadir
leucocyt
count
cell
per
haematocrit
platelet
count
per
creatinin
peak
mgdl
requir
haemodialysi
aspart
aminotransferas
total
bilirubin
level
reach
iul
mgdl
respect
ferritin
level
higher
ngml
triglycerid
mg
dl
develop
dissemin
intravascular
coagul
ddimer
ngml
inr
aptt
fi
brinogen
less
mgdl
ebv
pcr
continu
increas
copi
per
ml
copi
per
ml
high
dose
steroid
given
transfer
intens
care
unit
die
hospit
day
despit
maximum
support
autopsi
reveal
prolifer
macrophag
haemo
phagocytosi
bone
marrow
lymph
node
spleen
posit
immunohistochemistri
ebv
fi
gure
patient
met
criteria
ebvassoci
haemophagocyt
syndrom
includ
persist
fever
splenomegali
sever
pancytopenia
liver
test
abnorm
elev
ferritin
histolog
evid
haemophagocytosi
haemophagocyt
syn
drome
criteria
fulfi
lled
sinc
genet
mutat
analysi
evalu
natur
killer
nk
cell
cytotox
solubl
level
obtain
premortem
haemophagocyt
syndrom
haemophagocyt
lymphohistiocytosi
lifethreaten
clinico
patholog
entiti
characteris
impair
absent
function
nk
cell
cytotox
cell
dysregul
result
uncontrol
ineff
ectiv
immun
activ
lead
cellular
damag
multiorgan
dysfunct
well
prolifer
activ
benign
macrophag
haemophagocytosi
throughout
reticuloendotheli
system
caus
pancytopenia
hepatosplenomegali
lymphaden
opathi
haemophagocyt
syndrom
fi
rst
describ
scott
robbsmith
disord
divid
primari
genet
haemophagocyt
syndrom
secondari
reactiv
haemophagocyt
syndrom
panel
histor
distinct
help
diff
erenti
case
haemophagocyt
syndrom
present
infanc
caus
high
rate
mortal
defi
ned
primari
haemophago
cytic
syndrom
case
syndrom
caus
aetiolog
present
later
life
better
prognosi
secondari
haemophagocyt
syndrom
howev
distinct
may
artifi
cial
first
primari
haemophagocyt
syndrom
occur
age
infanc
earli
childhood
second
underli
genet
mutat
found
primari
haemophagocyt
syndrom
patient
third
primari
secondari
syndrom
precipit
infect
fi
nalli
secondari
case
haemophagocyt
syndrom
carri
higher
mortal
seen
primari
haemophagocyt
syndrom
genet
haemophagocyt
syndrom
divid
two
subgroup
depend
whether
associ
immun
defi
cienci
famili
form
haemophagocyt
lymphohistiocytosi
fi
rst
describ
estim
occur
one
birth
famili
haemophagocyt
lymphohistiocytosi
manifest
fi
rst
year
life
case
sever
genet
mutat
occur
sporad
case
haemophagocyt
syndrom
describ
knowledg
fi
rst
report
case
haemophagocyt
syndrom
patient
holtoram
syndrom
disord
caus
mutat
transcript
factor
role
cardiac
limb
format
holtoram
syndrom
associ
immun
defi
cienci
state
result
increas
suscept
infect
infect
import
role
aetiolog
haemophagocyt
syndrom
howev
data
exist
incid
infectionassoci
diseas
haemophagocyt
syndrom
clinic
mimic
infect
obscur
coexist
infect
precipit
primari
secondari
haemophagocyt
syndrom
better
understand
pathophysiolog
haemophago
cytic
syndrom
may
clarifi
interact
infect
immun
system
fi
rst
descript
virusassoci
haemo
phagocyt
syndrom
made
risdal
colleagu
compris
patient
immunocompromis
patient
subsequ
report
known
genet
acquir
immunodefi
cienci
review
publish
case
janka
colleagu
show
children
diagnos
infectionassoci
haemophagocyt
syndrom
half
east
asia
overal
mortal
children
die
higher
patient
ebvassoci
diseas
children
ebv
die
ebv
trigger
viru
children
defect
granul
perforingranzym
mediat
cytotox
import
kill
infect
cell
termin
immun
respons
seem
underli
factor
predispos
individu
haemophagocyt
syndrom
sinc
sever
genet
loci
relat
activ
perforin
granzym
granul
associ
genet
haemophagocyt
syndrom
thu
explain
impair
absent
function
nk
cell
cytotox
cell
characterist
diseas
apoptosi
famili
haemophagocyt
lymphohistiocytosi
also
describ
pathophysiolog
acquir
haemophagocyt
syndrom
fulli
understood
defi
cienci
cytolyt
activ
result
persist
activ
lymphocyt
histiocyt
uncontrol
immun
respons
lead
hypersecret
proinfl
ammatori
cytokin
interferon
tumour
necrosi
factor
interleukin
interleukin
interleukin
interleukin
interleukin
macrophag
colonystimul
factor
mcsf
upregul
adhes
molecul
mhc
ii
molecul
monomacrophag
expans
infl
ammatori
monocyt
ie
increas
express
mediat
secret
activ
histiocyt
lymphocyt
infi
ltrate
diff
erent
tissu
exagger
infl
ammatori
respons
respons
necrosi
organ
failur
result
uncontrol
prolifer
phagocyt
activ
histiocyt
diagnosi
haemophagocyt
syndrom
reli
clinic
laboratori
histopatholog
fi
nding
diagnost
guidelin
propos
histiocyt
societi
updat
panel
sinc
therapi
life
save
clinic
criteria
occur
late
diseas
necessari
fulfi
l
criteria
initi
therapi
main
symptom
haemo
phagocyt
syndrom
fever
splenomegali
jaundic
hepatomegali
lymph
adenopathi
rash
neurolog
sign
also
common
tabl
hallmark
laboratori
fi
nding
cytopenia
profound
also
mark
liver
dysfunct
elev
ferritin
level
characterist
tabl
two
highli
diagnost
paramet
increas
plasma
concentr
alpha
chain
receptor
impair
nkcell
activ
elev
receptor
haemophagocyt
syndrom
suggest
activ
lymphocyt
correl
prognosi
histopatholog
activ
macrophag
engulf
leucocyt
erythrocyt
platelet
precursor
cell
typic
fi
nding
haemophagocytosi
seen
organ
particularli
bone
marrow
lymph
node
liver
spleen
haemophagocytosi
absent
initi
biopsi
specimen
biopsi
need
repeat
diagnosi
haemophagocyt
syndrom
establish
search
underli
genet
rheumatolog
malign
diseas
possibl
infecti
trigger
undertaken
haemophagocyt
syndrom
highli
fatal
diseas
untreat
sinc
haemophagocyt
syndrom
rare
randomis
control
clinic
trial
test
potenti
treatment
done
immedi
aim
therapi
suppress
increas
infl
ammatori
respons
control
cell
prolifer
use
immunosuppress
immunomodulatori
agent
cytotox
drug
treatment
diff
er
children
adult
depend
underli
diseas
presenc
trigger
sever
symptom
patient
reactiv
haemophagocyt
syndrom
associ
infecti
pathogen
leishmaniasi
support
care
initi
sinc
pathogendirect
therapi
suffi
cient
control
diseas
apart
case
ebv
treatment
underli
infect
alon
reactiv
haemophagocyt
syndrom
associ
recoveri
patient
chemotherapi
use
dexamethason
cyclosporin
etoposid
adopt
histiocyt
societi
updat
use
sever
particularli
famili
ebvassoci
haemophagocyt
syndrom
case
patient
genet
haemophagocyt
syndrom
sever
refractori
haemophagocyt
syndrom
bone
marrow
transplant
consid
review
patient
arico
cowork
found
bone
marrow
transplant
recipi
superior
outcom
compar
nontranspl
patient
vs
recov
respect
studi
combin
chemotherapi
protocol
bone
marrow
transplant
children
show
probabl
surviv
year
case
children
surviv
proven
famili
case
children
surviv
report
spontan
regress
describ
monoclon
antibodi
rituximab
receptor
daclizumab
use
set
rheumat
diseas
malign
associ
haemophagocyt
syndrom
role
intraven
immunoglobulin
treat
haemophagocyt
syndrom
fulli
understood
use
earli
chanc
success
howev
intraven
immunoglobulin
combin
steroid
thought
inferior
etoposidecontain
regimen
use
growth
factor
granulocytecoloni
stimul
factor
gmcsf
exacerb
haemophagocyt
syndrom
haemophagocyt
syndrom
associ
varieti
viral
bacteri
fungal
parasit
infect
viral
infect
associ
syndrom
includ
ebv
cytomegaloviru
human
herpesviru
hiv
infl
uenza
viru
parvoviru
hepat
viru
enteroviru
howev
ebv
common
trigger
agent
ebvassoci
haemophagocyt
syndrom
case
occur
appar
immunocompet
children
adolesc
howev
ebvassoci
haemophagocyt
syndrom
also
occur
set
famili
eg
famili
haemophagocyt
lymphohistiocytosi
nonfamili
eg
xlink
lymphoprolif
syndrom
immun
defi
cienci
well
infecti
mononucleosi
chronic
activ
ebv
infect
lymphoprolif
disord
eg
nk
tcell
leukaemia
lymphoma
ebvassoci
haemophagocyt
syndrom
high
incid
asian
countri
possibl
presenc
pathogen
ebv
strain
also
describ
countri
usa
europ
japan
least
case
ebvassoci
haemophagocyt
syndrom
per
year
paediatr
popul
peak
incid
occur
year
slightli
higher
frequenc
girl
boy
ebvassoci
haemophagocyt
syndrom
occur
commonli
set
reactiv
primari
infect
ebv
typic
infect
replic
b
cell
ebvspecifi
c
cytotox
cell
usual
requir
regul
infect
b
cell
produc
memori
cell
limit
number
individu
ebv
infect
nk
cell
induc
ebvpersist
infect
monoclon
oligoclon
prolifer
ebvassoci
haemophagocyt
syndrom
ebv
infect
primari
cell
failur
produc
suffi
cient
number
ebvspecifi
c
cytotox
cell
suggest
nk
tcell
dysfunct
typic
cytokin
storm
seen
haemophagocyt
syndrom
pronounc
ebvassoci
diseas
caus
haemophagocytosi
organ
dysfunct
serolog
method
help
determin
ebvassoci
haemophagocyt
syndrom
occur
set
acut
infect
result
reactiv
process
howev
method
carri
diagnost
limit
delay
posit
diffi
culti
result
interpret
variat
treatment
absenc
quantifi
cation
ebv
detect
quantifi
cation
ebv
nucleic
acid
pcr
therefor
import
assess
ebv
load
patient
ebvassoci
haemophagocyt
syndrom
help
determin
diagnosi
also
prognosi
effi
caci
therapi
even
though
ebv
peripher
blood
highli
associ
leucocyt
ebv
pcr
whole
blood
serum
need
measur
ebv
load
term
viral
replic
establish
greater
viral
load
seen
patient
ebvassoci
haemophagocyt
syndrom
compar
patient
infecti
mononucleosi
onset
infecti
mononucleosi
ebv
load
measur
realtim
pcr
copi
per
peripher
blood
mononuclear
cell
pbmc
dna
ebv
load
disappear
within
week
normal
increas
ebvcytotox
cell
howev
ebvassoci
haemophagocyt
syndrom
ebv
load
usual
copi
per
pbmc
dna
quantit
analysi
cellfre
ebv
genom
copi
number
month
therapi
ebvassoci
haemophagocyt
syndrom
assess
respons
treatment
carri
prognost
valu
ebv
load
also
found
associ
sever
diseas
ebvrel
diseas
genet
test
need
done
rule
confi
rm
presenc
underli
immunodefi
cienci
virus
associ
haemophagocyt
syndrom
ebvassoci
syndrom
carri
worst
prognosi
howev
aggress
therapi
condit
yield
good
result
longitudin
followup
patient
japan
treat
ebvassoci
haemophagocyt
syndrom
median
followup
month
show
surviv
patient
receiv
etoposidebas
regimen
patient
requir
bone
marrow
transplant
clinic
reactiv
seen
around
case
ebvspecifi
c
therapi
ineff
ectiv
treat
ebvassoci
haemophagocyt
syndrom
possibl
ebv
respond
poorli
aciclovir
shown
studi
use
drug
treatment
infecti
mononucleosi
larger
trial
need
assess
eff
ectiv
specifi
c
antiebv
therapi
ebvassoci
haemophago
cytic
syndrom
etoposidecontain
regi
men
seem
crucial
role
cure
etoposid
high
activ
histiocyt
diseas
inhibit
ebv
nuclear
antigen
ebvinfect
cell
mortal
found
time
higher
patient
ebvassoci
haemophagocyt
syndrom
receiv
etoposid
within
fi
rst
week
diagnosi
compar
receiv
earli
therapi
etoposid
bone
marrow
transplant
necessari
patient
ebvassoci
haemo
phagocyt
syndrom
famili
haemophagocyt
lymphohistiocytosi
xlink
lympho
prolif
syn
drome
chronic
activ
ebv
infect
refractori
diseas
cytomegaloviru
associ
haemophagocyt
syndrom
healthi
patient
well
patient
infl
ammatori
bowel
diseas
rheumatolog
diseas
transplant
recipi
outlook
patient
cytomegalovirusassoci
haemophagocyt
syndrom
poor
four
fi
patient
less
condit
die
accord
haemophagocyt
lymphohistiocytosi
japanes
registri
howev
recent
report
shown
use
specifi
c
anticytomegaloviru
therapi
cytomegaloviru
immunoglobulin
foscarnet
ganciclovir
cur
disord
patient
haemophagocyt
syndrom
describ
literatur
case
occur
set
kaposi
sarcoma
multicentr
castleman
diseas
immunocompromis
host
eight
patient
hiv
posit
two
patient
renal
transplant
recipi
nine
patient
recov
fi
treat
etoposidecontain
regimen
four
treat
ganciclovir
foscarnet
hiv
hiv
alon
presenc
opportunist
nonopportunist
infect
malign
associ
haemophagocyt
syndrom
although
associ
hiv
haemophagocyt
syndrom
rare
like
condit
underdiagnos
sinc
hiv
haemophagocyt
syndrom
share
mani
clinic
laboratori
similar
around
bone
marrow
biopsi
hiv
patient
initi
highli
activ
antiretrovir
therapi
haart
show
haemophagocytosi
one
autopsi
studi
haemo
phagocytosi
found
hiv
patient
recent
review
patient
hivassoci
haemophagocyt
syndrom
male
median
age
year
rang
year
patient
opportunist
infect
malign
suggest
possibl
role
hiv
trigger
haemophagocyt
syndrom
patient
fever
hepatomegali
splenomegali
pancytopenia
common
patient
count
less
cell
per
mean
cell
per
recoveri
note
patient
wors
outcom
seen
patient
count
less
cell
per
patient
inform
regard
treatment
avail
three
receiv
antiretrovir
drug
one
respond
haart
two
patient
receiv
chemotherapi
consist
haemophagocyt
lymphohistiocytosi
protocol
intraven
immunoglobulin
six
patient
steroid
fi
patient
splenectomi
two
patient
occasion
use
haemophagocyt
syndrom
initi
present
hiv
infect
eight
patient
acut
hivassoci
haemophagocyt
syndrom
report
literatur
even
though
one
patient
receiv
haart
eight
patient
surviv
hivassoci
haemophagocyt
syndrom
also
describ
set
immun
reconstitut
infl
ammatori
syndrom
infl
uenzaassoci
haemophagocyt
syndrom
rare
condit
describ
diff
erent
infl
uenza
viruseseg
human
infl
uenza
avian
infl
uenza
swine
infl
uenza
seen
immunocompromis
immunocompet
host
patient
sever
avian
infl
uenza
infect
symptom
laboratori
fi
nding
similar
seen
haemophagocyt
syndromemainli
enceph
organ
dysfunct
accompani
haemophagocytosi
pancytopenia
cytokin
storm
reactiv
haemo
phagocytosi
common
patholog
fi
nding
recombin
haemagglutinin
viru
may
suppress
perforin
grand
round
express
human
cell
may
reduc
cytotox
cell
prevent
kill
cell
result
persist
cell
lead
mark
lymphoprolifer
hyperproduct
macrophag
overactiv
sinc
mortal
caus
haemophagocyt
syndrom
high
around
antivir
drug
ineff
ectiv
author
suggest
treatment
modifi
ed
protocol
shorter
cours
etoposid
dexamethason
howev
randomis
studi
vietnam
patient
haemophagocyt
syndrom
die
despit
receiv
steroid
patient
parvovirusassoci
haemophagocyt
syndrom
common
underli
diseas
hereditari
spherocytosi
half
patient
women
older
year
age
despit
fact
patient
receiv
specifi
c
therapi
patient
surviv
suggest
parvoviru
haemo
phagocyt
syndrom
carri
better
prognosi
compar
virusassoci
haemophagocyt
syndrom
fulmin
hepat
mimic
haemophagocyt
syndrom
hepat
viru
hav
found
commonli
associ
haemophagocyt
syndrom
hepat
virus
eight
patient
hav
haemophagocyt
syndrom
surviv
steroid
given
frequent
enterovirusassoci
haemophagocyt
syndrom
describ
nine
paediatr
patient
fi
underli
ill
fi
die
despit
therapi
intraven
immunoglobulin
use
seven
patient
variabl
success
rate
virus
found
associ
haemophagocyt
syndrom
includ
adenoviru
measl
mump
rubella
dengu
hantaviru
sever
acut
respiratori
syndrom
bacteriaassoci
haemophagocyt
syndrom
mycobacteria
spp
case
haemophagocyt
syndrom
associ
tuberculosi
publish
recent
review
patient
male
median
age
year
half
patient
underli
comorbid
fever
present
case
organomegali
case
patient
evid
extrapulmonari
tuberculosi
pancytopenia
particularli
thrombo
cytopenia
common
patient
patient
receiv
therapi
either
antitubercul
drug
alon
nine
patient
combin
antitubercul
drug
immunomodulatori
therapi
patient
immunomodulatori
treatment
mostli
consist
steroid
two
patient
underw
splenectomi
two
plasmapheresi
patient
receiv
combin
immunomodulatori
antitubercul
treatment
seven
nine
patient
receiv
antitubercul
treatment
alon
surviv
patient
receiv
treatment
die
haemo
phagocyt
syndrom
also
seen
develop
adjuv
intraves
bcg
therapi
bcg
vaccin
incid
bacteriaassoci
haemophagocyt
syndrom
vari
studi
haemophagocyt
syndrom
associ
pyogen
bacteria
sometim
carri
better
prognosi
virusassoci
haemophagocyt
syndrom
howev
associ
sepsi
bacteriaassoci
haemophagocyt
syndrom
fatal
unless
time
appropri
support
care
antibiot
given
campylobact
fusobacterium
mycoplasma
chlamydia
legionnella
typhoid
rickettsia
brucella
ehrlichia
lyme
diseas
well
bacteri
infect
identifi
ed
patient
haemophagocyt
syndrom
leishmania
donovani
caus
haemophagocyt
syndrom
also
mimic
syndrom
organomegali
cytopenia
bone
marrow
aspir
determin
correct
diagnosi
treatment
leishmaniasisassoci
haemophagocyt
syndrom
amphotericin
b
result
cure
malaria
plasmodium
falciparum
plasmodium
vivax
toxoplasma
babesiosi
strongyloidiasi
also
describ
haemophagocyt
syndrom
travel
histori
crucial
help
determin
trigger
agent
patient
return
endem
region
haemophagocyt
syndrom
either
associ
yeast
eg
candida
spp
cryptococcu
spp
pneumocysti
spp
mould
eg
histoplasma
spp
aspergillu
spp
fusarium
spp
haemophagocyt
syndrom
associ
fungal
infect
occur
commonli
set
aid
lymphoma
chronic
steroid
use
transplant
recipi
data
review
identifi
ed
search
medlin
refer
relev
articl
period
januari
septemb
search
term
includ
hemophagocyt
syndrom
haemophagocyt
syndrom
hemophagocytosi
haemophagocytosi
histiocyt
hemophagocytosi
histiocyt
haemophagocytosi
hemophagocyt
lymphohistiocytosi
haemophagocyt
lymphohistiocytosi
histiocytosi
virus
epstein
barr
viru
herpesviru
human
cytomegaloviru
hiv
infect
infl
uenza
human
parvoviru
hepat
enteroviru
bacteria
parasit
fungi
english
french
languag
paper
review
clinician
need
awar
occurr
haemophagocyt
syndrom
patient
persist
fever
organomegali
cytopenia
set
infecti
process
particularli
ebv
infect
manag
syndrom
reli
earli
diagnosi
identifi
cation
trigger
pathogen
underli
diseas
control
lymphocytemacrophag
prolifer
activ
specifi
c
antimicrobi
therapi
benefi
cial
select
case
sever
case
treat
chemotherapi
gener
etoposidecontain
regimen
bone
marrow
transplant
treatment
famili
sever
persist
nonfamili
case
declar
confl
ict
interest
